---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-23-000050"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2023-11-30T23:59:59+00:00"
generated_at: "2026-06-07T19:48:40.056328+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.82
calibrated_materiality_score: 0.82
confidence: "high"
source: SEC EDGAR
---

# Altimmune reports Phase 2 obesity trial: 15.6% mean weight loss with pemvidutide 2.4 mg at Week 48

## Summary
- Mean weight loss of 15.6% on 2.4 mg dose vs 2.2% placebo; near-linear trajectory at end of treatment.
- Over 30% of subjects achieved ≥20% weight loss on 2.4 mg; 83.9% achieved ≥5% weight loss.
- Robust reductions in serum lipids and blood pressure without cardiac safety imbalances; zero MACE events.
- Discontinuation rates higher at higher doses: 19.6% (2.4 mg) vs 6.2% placebo; most due to GI AEs in first 16 weeks.
- Only one drug-related SAE (vomiting at 2.4 mg); nausea/vomiting predominantly mild to moderate.

## SEC filing metadata
- accession: 0001326190-23-000050
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2023-11-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.82
- calibrated_materiality_score: 0.82
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/0001326190-23-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/alt-20231130x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-23-000050
- JSON: https://secwatch.observer/filing/0001326190-23-000050.json
- Plain text: https://secwatch.observer/filing/0001326190-23-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.